1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
- Contribution to journal › Article
- 2006
-
Mark
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: Present and future
Ueckert, Stefan ; Hedlund, Petter LU ; Andersson, Karl-Erik LU
; Truss, Michael C.
; Jonas, Udo
and Stief, Christian G.
(2006)
In European Urology
50(6).
p.1194-1207
- Contribution to journal › Scientific review
- 2002
-
Mark
New directions for erectile dysfunction therapies.
Andersson, Karl-Erik LU
and Hedlund, Petter
LU
(2002)
In International Journal of Impotence Research
14 Suppl 1.
p.82-92
- Contribution to journal › Article
- 1998
-
Mark
Various phosphodiesterase subtypes mediate the in vivo antilipolytic effect of insulin on adipose tissue and skeletal muscle in man
Enoksson, S ; Degerman, Eva LU
; Hagstrom-Toft, E
; Large, V
and Arner, P
(1998)
In Diabetologia
41(5).
p.560-568
- Contribution to journal › Article
-
Mark
The effect of selective phosphodiesterase inhibitors on mucociliary activity in the upper and lower airways in vitro
- Contribution to journal › Article
- 1995
-
Mark
Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family)
Manganiello, Vincent C ; Taira, Masato ; Degerman, Eva LU
and Belfrage, Per
LU
(1995)
In Cellular Signalling
7(5).
p.445-455
- Contribution to journal › Article